Cabo/Ifos in Ewing Sarcoma and Osteosarcoma (CaIRS trial)

Cabo/Ifos in Ewing Sarcoma and Osteosarcoma (CaIRS trial)

Contact

 If you are interested in participating in the study or want to learn more, please get in touch. Contact us
This study is now recruiting. Learn more about enrolling here.

Description
This study enrolls patients between 5 and 40 years of age with a diagnosis of Ewing sarcoma (including Ewing-like sarcoma) or osteosarcoma that has progressed on or relapsed after upfront initial therapy. The purpose of this study is to find the best dose of a drug called cabozantinib (“the study drug”) to give to patients in combination with a routine chemotherapy drug called ifosfamide. 

Eligibility and criteria
IRB Number:
22-019876
Eligible age range:
5 years - 40 years
Clinical trial phase:
Phase I
Official title:
A phase I trial of Cabozantinib (XL184) in combination with high-dose Ifosfamide in adults and children with relapsed/refractory Ewing sarcoma and osteosarcoma (CaIRS trial)

What to expect
As a participant in the research, you will:
  • Take cabozantinib (the study drug) by mouth once a day, in combination with routine chemotherapy drug ifosfamide given intravenously on days 1-5 of each cycle
  • Complete frequent clinic visits at CHOP Philadelphia campus 
  • Have frequent blood tests
  • Have EKGs and echocardiograms for clinical care purposes
  • Have periodic imaging performed as part of your regular cancer care to evaluate your response to treatment
  • Have research genetic tests (if not previously done clinically)
  • Submit leftover tissue samples to the study repository
  • Have fresh tissue samples collected (if you have a routine biopsy)

Related specialties
Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.